SCHEMBL6744223

SCHEMBL6744223

O=c1[nH]c(CNc2ccc([N+](=O)[O-])cc2)nc2ccc3ccccc3c12

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 3/20 0.49
SMN1; SMN2 Q16637 2/20 0.49
NPC1 O15118 1/20 0.49
GAA P10253 1/20 0.49
RAB9A P51151 1/20 0.49
TYMS P04818 2/20 0.49
MEN1 O00255 3/20 0.44
KMT2A Q03164 3/20 0.44
PTPRF P10586 1/20 0.42
PTPN2 P17706 1/20 0.42
PTPN1 P18031 1/20 0.42
PTPN11 Q06124 1/20 0.42
NQO2 P16083 1/20 0.42
TNKS O95271 1/20 0.42
GUSB P08236 1/20 0.42
NLRP3 Q96P20 1/20 0.42
TNKS2 Q9H2K2 1/20 0.42
PARP2 Q9UGN5 1/20 0.42
KDM4E B2RXH2 1/20 0.42
GLA P06280 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6450940 0.77 TYMS (0.53) MAPTRAB9ATYMS
SCHEMBL6449026 0.76 TYMS (0.57) TYMS
SCHEMBL6744219 0.71 MAPT (0.46) MAPTSMN1; SMN2GAAMEN1KMT2A
SCHEMBL23882597 0.70 RAB9A (0.78) MAPTSMN1; SMN2NPC1GAARAB9A
SCHEMBL5162135 0.69 MAPT (0.68) MAPTSMN1; SMN2GAAMEN1KMT2A
SCHEMBL6653100 0.67 TYMS (1.00) MAPTSMN1; SMN2NPC1GAARAB9A
SCHEMBL6652840 0.65 TYMS (0.59) MAPTSMN1; SMN2NPC1GAARAB9A
SCHEMBL30589037 0.65 TYMS (1.00) TYMS
SCHEMBL6654365 0.65 TYMS (1.00) TYMS
SCHEMBL32666088 0.65 KDM4E (0.63) MAPTSMN1; SMN2RAB9AMEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20040057990-A1 Liposomal benzoquinazoline thymidylate synthase inhibitor formulations OSI PHARMACEUTICALS, INC. 2004-03-25 US disclosed
US-6689381-B2 LIPOSOME COMPRISING PHOSPHATIDYLCHOLINE, CHOLESTEROL, AS WELL AS BENZOQUINAZOLINE THYMIDYLATE SYNTHASE INHIBITOR; IMPROVED PHARMACOKINETICS AND EFFICACY AS ANTI-TUMOR AGENTS COMPARED TO FREE DRUG OSI PHARMACEUTICALS, INC. 2004-02-10 US disclosed
US-20020034538-A1 Liposomal benzoquinazolne thymidylate synthase inhibitor formulations GILEAD SCIENCES, INC. 2002-03-21 US disclosed
US-5663337-A ENZYME, ANTITUMOR GLAXO WELLCOME INC. (US) 1997-09-02 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020034538-A1 Liposomal benzoquinazolne thymidylate synthase inhibitor formulations TYMS, TYMP, CTPS1 MAPT 1747/4885SMN1; SMN2 4158/4885NPC1 87/4885
US-20040057990-A1 Liposomal benzoquinazoline thymidylate synthase inhibitor formulations TYMS, TYMP, CTPS1 MAPT 1712/4885SMN1; SMN2 4201/4885NPC1 83/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.